WaferGen Bio-systems Inc

WaferGen Bio-systems — Investor Presentation (January 2008)

31 slides from WaferGen Bio-systems's investor presentation, Jan 7, 2008

  1. Slide 1: Investor Presentation

    OO, WaferGen Biosystems WaferGen Bio-Systems, Inc. WGBS.OB Investor Presentation January 7, 2008 © 2008 WaferGen Bio-Systems, Inc.

  2. Slide 2: Forward-looking statements

    — WK ice. — WaferGen- This presentation contains ‘forward-looking statements’ within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, including without limitation those statements regarding WaferGen’s ability to exploit com

  3. Slide 3: WaferGen's Mission

    WaferGen’s Mission WaferGen- To be the platform of choice for genetic analysis and cell monitoring enabling genomics and cell biology from research to clinic. ferGen Bio-systems, Inc.

  4. Slide 4: About WaferGen (WGBS.OB)

    AboutWaferGen (WGBS.OB) sant see = Operations began in April 2003 = Located in Silicon Valley in Fremont, CA = SmartChip™: Flagship product for gene expression & genotyping = First gene expression and genotyping platform to combine high- throughput capability and cost efficiencies of microarrays, wi

  5. Slide 5: SmartChip System Solution: New paradigm shift

    M Opportunit N00 Se WaferGen- New paradigm shift - SmartChip™ System Solution First whole genome / high throughput gene expression Real-Time PCR platform = Unmatched performance ona WaferGen’s = High sensitivity Microaray SmartChip = Large dynamic range of 6 logs today Real-Time PCR = High throughpu

  6. Slide 6: Gene Expression & Genotyping Total Addressable Market

    WE a WaferGen- Mb ii Gene Expression & Genotyping CAGR 10-16% Gene Expression & Genotyping - Total Addressable Market ($Billion) $6.0 $5.0 $4.0 $3.0 $2.0 $1.0 |] $4.74 $1.93 $2.42 $2.33 $0.0 $2.56 $2.81 $3.10 2006 2007E 2008E 2009E 2010E 2011E 2012E Gene Expression o Genotyping | BRR nso = {UBS Imes

  7. Slide 7: Competitor leaders and global revenue

    dar - WK WM ft eas WaferGen- ABI leader in Real-Time PCR Affymetrix leader in Whole Genome Gene Expression Illumina leader in Whole Genome Genotyping Global Revenue ($Million) $185 $310 $400 2003 2004 2005 2006 2007E 2008E B Illumina @ ABI @ Affymetrix Note: ABI revenue is for Real-Time PCR & RNAi S

  8. Slide 8: Attractive Business Model

    Attractive Business Model be azor & razor blade” B e ode ong gro arg 8 high valuatio Affymetrix ABI Illumina "Revenue per unit # of units - Installed base 2006 Product Revenue Market Cap © 2008 WaferGen Bio-systems, Inc.

  9. Slide 9: Gene Expression: Challenges

    Gene£xpression: Challenges OO WaferGen- There are currently two ways to conduct gene expression analysis Microarray (hybridization) * Microarrays less sensitive than real-time PCR, poor in discriminating small changes in expression, with only 2-3 logs of dynamic range * Interrogates only 20-40% of e

  10. Slide 10: WaferGen SmartChip versus current methods

    wr NX WaferGen No Yes Whole Genome Yes Dynamic Range 2to 3 logs 6 logs Quantitative Semi Yes Murcwersuiscem 1 Sample/ 30,000 genes | Few samples (96-384) per run x fewgenes 100,000 starting copies 4-10 starting copies Project Process Multiple steps Two steps Whole Genome Days Months Assay e $1000 pl

  11. Slide 11: Increased use of gene expression from research to clinic

    OO WaferGen- ee ts pee Increase use of Gene Expression for biomarker discovery & toxicology Research ge Clinic _ Diagnostics w Genes & Many Samples AEE MOUS mage ne (Many Genes & Few, Samples ee _| Sah) ——— Ei solution from discovery through molecular diagnostics WaferGen’s SmartChip™ platform will

  12. Slide 12: Real-Time PCR Results in One Day

    NOOO WaferGen- System Action: J . 2 Real-Time PCR Results in One Day ient Adds: Results: ple + Metal lon One Day Whole genome (WGG) Real-Time PCR results © 2008 WaferGen Bio-systems, Inc. 12

  13. Slide 13: SmartChip workflow

    WaferGen- cm ys Sealed SmartChip shipped to customer on ice Panel of genes selected Selected genes deposited on SmartChip using Wafergen’s factory dispenser @ Customer lab . oes De a) w= i ex=> // ‘Sample loading Automated analysis of Ct, Tm ete. Wafergen Cycler Flagging of suspect reactions. Export

  14. Slide 14: Clients Will Switch to SmartChip

    Cliénts-Will Switch te.SmartChip™ N00 WaferGen- Pharmaceutical Clinical Trial Workflow Comparison: TaqMan & SmartChip™ for a 240 patients, 960 Samples, 25 genes Real-time PCR reactions with TaqMan Real-time PCR reactions on SmartChip™ + RNA isolation/ quantitation’ reverse transcription + RNA isolat

  15. Slide 15: SmartChip Product Road Map

    rtGhip™ - Product. Road Map Oe WaferGen- SmartChip™ System Milestones Material Test Bench Detection Prototype 2007 2008 2009 HQ 2Q 30 40} 10 20 30 40] 10 20 30 4Q Development Final Chip Prototype & Toxicology Gene Panel Assays Alpha Testing SmartChi'™ System Beta Testing SmartChip'™ System with Phar

  16. Slide 16: SmartChip development progress

    a W. Demonstrated feasibility of small volume, single- We laferGen step enzyme assays; initial batch of 949 100 nL Beene assays developed. Whole Genome chip with 31,750 wells in an SBS format tested and finalized. Each well will support a qPCR reaction of 100 nL. Alpha instrument with sample dispens

  17. Slide 17: Assay Development Status

    Assay Development Status eee en- Oncology Toxicology _ Total Assays designed 900 49 949 Primers ordered 900 48 948 Assays Tested 900 48 948 Assays Passed 879 48 927 Assays failed 21 0 21 8 WaferGen Bio-systems, Inc.

  18. Slide 18: Nano-volume qPCR: Demonstration of Assay Sensitivity

    TotalRNA: SYBR'\Green Nano=volume QPGR:Demonstration of Assay sensitivity; ERBB2 Gene Expression In MCF-7 NOG WaferGen- To00pe ‘10ul Wore ‘ul sa 4 3 s00nL Pat 10pg , singe cell 2008 WaferGen Bio-systems, 1 18

  19. Slide 19: Assay Performance Comparison

    ERBB2 Expression in MCF-7 RNA os $20 fa ABI Taq 10 mWelerGen 5 ° 20008 2008 ang AmtoF RNA/x0 108 Wafer: Meanct Assay-Performance.Compariso NO WaferGen- HPRT Expression in MCF-7 RNA = ABITaqman mWalerGen 2003 4003 ans ‘Amt of INA/xn ems, Inc. 19

  20. Slide 20: SmartChip Business Strategy

    SmartChip™ Business-Strategy sant see Market the first whole genome/high throughput gene expression Real-time PCR platform to pharmaceutical/biotech companies & academic institutions Initial Focus: = Cancer, toxicogenomics, clinical research & biomarker discovery Follow-on Application: = Whole genom

  21. Slide 21: Novel Platform for Stem Cell & Cell Biology Researchers

    OG WaferGen- Novel Platform for Stem Cell & Cell Biology Researchers The first of a kind fluidics integrated micro-incubator for stem cell & SmartSlide™ platform total addressable markets exceed $970 million sLive cell imaging research applications ($770 million) *Clinical applications such as: «In-

  22. Slide 22: SmartSlide Market

    SmartSlide™ Market N00 SmarSlide™ Market _ a = SmartSlide’s total addressable market cell imaging is represented by the total number of research laboratories that own/use inverted microscopes for cell research = 35,150 research labs throughout the world own/use inverted microscopes for cell research

  23. Slide 23: SmartSlide Customers

    rtSlide™ Cust OO Leveraging SmartSlide™ Customers for SmartChip™ Early-Adopter Academic & Clinical Customers = Harvard = Mayo Clinic = Sloan Kettering = UCLA = NASA = VA Medical Center = National Institute of Health Early-Adopter Pharmaceutical Company Customers = Abbott Labs = Eisai Research = Celp

  24. Slide 24: SmartSlide Business Strategy

    SmartSlide™ Business-Strategy sant see Market the first integrated fluidics exchange micro- incubator to stem cell & primary cell researchers, as well as cell biologists Initial Focus: = Stem cell and primary cell research; imaging applications Follow-On Applications: = In-vitro fertilization, cance

  25. Slide 25: Recent SmartSlide Developments

    Recent.SmartSlide™ NO0e Developments WaferGen- = First Customer Shipment (FCS) of SmartSlide 200 Micro Incubator to renowned stem cell researcher Dr. Paul J. Simmons, Ph.D of the University of Texas-Houston Institute of Molecular Medicine Center for Stem Cell Research. The SmartSlide 200 is the firs

  26. Slide 26: Status of Intellectual Property

    Status-ofintellectual*Property sant see Patent applications and in-licensed patents covering products, methodologies, system integration & applications = Patent applications have been filed for: = High-throughput Real-Time PCR = The SmartChip™ Product = Pico-dispenser = NanoPMT array = Floating gate

  27. Slide 27: Management Team

    OO WaferGen- Strong track record of creating shareholder value (>$12 billion) & commercializing successful products for leading biotech _ companies Alnoor Shivji - Co-Founder, Chairman & CEO + Mr. Shiyji has had multiple successful experiences starting & managing high-tech companies * Founded or co-

  28. Slide 28: Management Team (continued)

    t Tea =e NOE ‘ : —S WaferGen- Terry W. Osborn, Ph.D., MBA - Chief Operating Officer = VP & GM at Nichols Institute; helped grow revenues from $55 million to $300 million. =CEO of Gene Express; commercialized & launched genomic biomarker products to blue-chip pharmaceutical customers Victor Joseph -

  29. Slide 29: Recent Corporate Developments

    ecent Corporate Developments N00 = Completed $12 Million Private Placement = Strengthened Corporate Leadership = Dr. David Gelfand, world-renowned expert on PCR, named Chief Scientific Officer = Dr. Eugene Bower, former Dean of Medicine at Stanford, named Chairman of Scientific Advisory Board = Addi

  30. Slide 30: Investment highlights

    NWO — WaferGen- WaferGen’s SmartChip™ System has the potential to do in a single day what now takes competitors weeks or months at a fraction of the cost WaferGen has the opportunity to standardize SmartSlide™ as the platform of choice for stem cell, primary cell researchers & cell biologists The ma

  31. Slide 31: Contact Info

    Contsetinto > _alfes WaferGen- Alnoor Shivji, Chairman & CEO ashivji@wafergen.com +1 (408) 455-3451 46531 Fremont Blvd Fremont, CA 94538 aferGen Bio-systems, Ine.

WaferGen Bio-systems — Investor Presentation (January 2008) on 6ix